/In Vitro Diagnostics
In a four-year deal, Celera Corp. has licensed Abbott Laboratories Inc. exclusive rights to distribute its CE-Marked KIF6...
Deals Shaping the Medical Industry (10/2010)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions
More from Archive
More from In Vivo
• By
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
• By
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
• By
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.